Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (371-380 of 443) with videos related to

Pageof 45
Sort By:
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
Elife|November 9, 2021
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modelingJoseph D Butner, Geoffrey V Martin, Zhihui Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Journal for Immunotherapy of Cancer|October 27, 2020
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stromaHampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, et al.
British Journal of Cancer|April 3, 2020
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumoursDavid S Hong, Yoon-Koo Kang, Mitesh Borad, et al.
Journal for Immunotherapy of Cancer|September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapyHari Menon, Dawei Chen, Rishab Ramapriyan, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Pageof 45

Showing results (371-380 of 443) with videos related to

Sort By:
Pageof 45
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
Elife|November 9, 2021
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modelingJoseph D Butner, Geoffrey V Martin, Zhihui Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Journal for Immunotherapy of Cancer|October 27, 2020
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stromaHampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, et al.
British Journal of Cancer|April 3, 2020
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumoursDavid S Hong, Yoon-Koo Kang, Mitesh Borad, et al.
Journal for Immunotherapy of Cancer|September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapyHari Menon, Dawei Chen, Rishab Ramapriyan, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Pageof 45